A Phase 1b Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX51107 in Subjects with Advanced Malignancies
A study for patients with solid tumors, lymphoma, acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) using study drug PLX51107
Sponsor: Plexxikon
Enrolling: Male and Female Patients
IRB Number: AAAQ9209
U.S. Govt. ID: NCT02683395
Contact: Richard Carvajal MD: 646-317-6041 / rdc2150@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the safety and effectiveness of study drug PLX51107 on patients with advanced malignancies such as solid tumors, lymphoma, AML or MDS. The participants in this study will be the first people to receive PLX51107. PLX51107 works by targeting and inhibiting certain activities within cells that promote tumor growth. By inhibiting these activities, PLX51107 may help to stabilize or reduce the growth of tumor cells. PLX51107 has shown anti-cancer activity in laboratory studies; however, it is not yet known whether it will work in humans. We are looking for the highest dose of PLX51107 that can be given safely to research subjects/participants with your type of disease. We will also look at how your body absorbs and breaks down PLX51107 and how effective PLX51107 is in treating your disease.
This study is closed
Richard Carvajal, MD
Do You Qualify?
Have you been diagnosed with a solid tumor, lymphoma, AML or MDS? Yes No
Are you over the age of 18? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Richard Carvajal MD